De-risking
Drug R&D

Largest In Vivo Spontaneous Cancer Dataset and Clinical Trial Platform in the World with
1.7 Billion Datapoints

Our Science

Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs

Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics

Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma

“One of the biggest challenges in developing new cancer drugs is accessing the large amounts of clinical data you need to make reliable predictions about how the drug will affect a patient’s prognosis,” said James Zou, Chief AI scientist at Stanford Health and senior author of the study.

“Collecting this data in humans is slow and incredibly expensive, but by partnering with veterinarians and their canine patients we can use that clinical data to dramatically accelerate the development of novel cancer treatments that will benefit both dogs and their owners.”

“This study provides the most comprehensive genomic sequencing data on canine cancers, including several previously unsequenced types, and serves as a much-needed resource for comparative oncology,” said Shaying Zhao, a professor at the University of Georgia and a co-author of the study.

“Our research shows that not all hemangiosarcomas are made equal,” said Cheryl London, the Associate Dean for Research and Graduate Education at Cummings School and a co-lead author on the paper. “This study shows how genomic sequencing of hemangiosarcomas can provide data to help veterinarians better understand prognosis for an HSA patient and help pet parents make better informed life-and-death decisions for their dogs,” adds London, who is also a veterinary advisor to One Health.

Veterinary oncology can inform human oncology, and vice versa — providing a better model for looking at drug performance, interrelationships, and more. Especially when you add in data (there’s no “doggy HIPAA!”) and networks to get a “living laboratory at scale”.

Listen to Amy Abernethy, advisor to One Health, on why she’s so excited about the impact of comparative oncology on our investor’s podcast The a16z Podcast.

Fireside Chat with Dr. Len Lichtenfeld, former Deputy Chief Medical Officer, American Cancer Society

Exclusive fireside chat with a distinguished trio of cancer experts: Dr. Len Lichtenfeld former Deputy Chief Medical Officer for the American Cancer Society (and FidoCure Scientific Advisory Board Member) with Christina Lopes, CEO, FidoCure and Dr. Gerry Post, Chief Medical Officer, FidoCure.

Hear first-hand about their 8-year journey together in the fight against cancer on both ends of the leash.

Oncology drug development is broken.

The canine model offers a unique and valuable perspective in the realm of medical research due to its significant advantages over the traditional mouse model. While mice models have been crucial in various studies, they come with a high failure rate when translating findings to human applications. Canine models, on the other hand, bridge the gap between preclinical research and clinical trials, serving as a more biologically relevant intermediary.

0 %

Failure In Mice To Human Translation

$ 0 B

To Bring Drugs to Market

0 Years

From R&D to Patients

Only 3-6% Patients Enroll in Clinical Trials

One Health canine data helped Eisai drug reach Phase 2 at Mass General

Our Canine Data in Hemangiosarcoma is concordant with human angiosarcoma.
AACR Journal

Today, with more data and ability to enroll the right canine cancer patient at the right time quickly, we can turbo charge human R&D and do what we did for Eisai 100x

TEDxBoston AI
Can dogs and AI fight cancer?

Reimagining the Patient: Dog

Canine biology closely mirrors human physiology and genetics, making it an excellent model for studying complex diseases, such as cancer. This increased relevance and reliability in mimicking human responses make the canine model a promising avenue for enhancing the success rate of research and ultimately improving human health outcomes.

Accelerated disease timeline
No standard of cancer care
Natural disease & intact immune system
Shared environment with humans

Imbruvica Case Study:
Dog data gave signal to unshelve blockbuster drug

Oncology R&D on Both Sides of the Leash

Our Solution

Canine Oncology Clinical Trials: a spontaneous disease model with genetic similarity to human tumors
The largest canine cancer clinico-genomic dataset: banked tumor tissue and ability to rapidly identify biomarker-selected patients for prospective trials
Access to longitudinal outcomes data in real time with repeat biopsy potential during treatment
Extensive canine cancer network and expertise

The Impact

Accelerate R&D through a better approximation of clinical disease in humans

De-risk R&D pipeline by providing proof-of-concept animal model to help reduce late-stage failures

Generate robust pre-clinical data to discover new predictive biomarkers and evaluate combination therapies for advancing novel treatments for human health

De-risking Drug R&D

Largest In Vivo Spontaneous Cancer Dataset and Clinical Trial Platform in the World with 1.7 Billion Datapoints